Evolus, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolus, Inc. on July 7, 2020, covering events occurring on July 6, 2020. The filing primarily addresses the entry into a material definitive agreement for debt financing and provides an update on a significant legal proceeding before the U.S. International Trade Commission (ITC).
Key Financial Metrics
- Debt Financing: Entered into a Convertible Promissory Note Purchase Agreement for an initial principal amount of $40 million with Daewoong Pharmaceutical Co., Ltd.
- Interest Rate: 3.0% per annum, payable semi-annually in arrears.
- Interest Payment Terms: Initially paid in kind (accrued to principal) while existing Oxford Debt remains outstanding; cash payments commence upon repayment of the Oxford Debt.
- Liquidity Position: Preliminary, unaudited cash, cash equivalents, and short-term investments were approximately $85 million as of June 30, 2020 (excluding the new Note proceeds).
- Conversion Terms: Initial conversion price of $13.00 per share, exercisable after 12 months. Full conversion of the initial principal would result in approximately 3,076,923 shares.
- Prepayment: Company may prepay without penalty starting 27 months from issuance, subject to a 10-day notice period.
Material Changes and Agreements
The Company executed a Subordination Agreement with Daewoong and Oxford Finance, LLC, subordinating the new Note to obligations under the existing Loan and Security Agreement with Oxford Finance, LLC (dated March 15, 2019). The proceeds from the $40 million Note are intended for working capital and general corporate purposes. The transaction is exempt from registration under Rule 506(b) of Regulation D and Section 4(a)(2) of the Securities Act.
Outlook, Risks, and Legal Contingencies
- ITC Proceeding Update: An Administrative Law Judge (ALJ) issued a non-binding Initial Determination in the case "In the Matter of Certain Botulinum Toxin Products" (Investigation No. 337-TA-1145). The ALJ found a violation of Section 337 of the Tariff Act of 1930 and recommended a 10-year exclusion order. This ruling is subject to review by the full ITC.
- Ownership Limitations: Conversion of the Note is subject to a beneficial ownership limitation, preventing Daewoong and affiliates from exceeding 4.99% of outstanding common shares (increasable to 9.99% with notice).
- Financial Reporting: The liquidity figures provided are preliminary and subject to revision upon the release of full Q2 2020 financial results.
Investor Verification Checklist
- Verify the final audited cash and short-term investment balances in the upcoming Q2 2020 earnings release.
- Monitor the status of the ITC review of the ALJ's Initial Determination regarding the 10-year exclusion order.
- Review the full text of the Convertible Promissory Note (Exhibit 4.1) and Subordination Agreement (Exhibit 10.2) for specific covenants and default events.
- Track the funding date of the $40 million Note, which is scheduled for on or before July 31, 2020.
- Assess the impact of potential dilution if the Note is converted, noting the 4.99% ownership cap.